Management of von Willebrand disease with a factor VIII-poor von Willebrand factor concentrate: results from a prospective observational post-marketing study.

CONCLUSIONS: Results from this PMS increase the clinical experience of a FVIII-poor pdVWF in patients of all ages and VWD types including those with thrombotic risk factors and emphasize that giving FVIII is not always mandatory to effectively treat patients with severe VWD. PMID: 32445594 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32445594?dopt=Abstract

Source: Thrombosis and Haemostasis - May 22, 2020 Category: Hematology Authors: Goudemand J, Bridey F, Claeyssens S, Itzhar-Baïkian N, Harroche A, Desprez D, Négrier C, Chamouni P, Chambost H, Henriet C, Susen S, Borel-Derlon A Tags: J Thromb Haemost Source Type: research